Rigel Pharmaceuticals | RIGL - Spese Operative





Spese Operative Cambiamento Data
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 5.69B 6B 2026-09
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 11.55B 674M 2026-09
BioMarin Pharmaceutical USD 819.04M 5.5B 2026-09
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Celldex Therapeutics USD 649.47M 65.1M 2026-09
Daiichi Sankyo JPY 483.8B 5.85B 2026-09
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 198M 4.66M 2026-09
Heron Therapeutics USD 40.55M 1.46M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 94.5M 39.4M 2026-09
MacroGenics USD 42.87M 21.68M 2026-06
Neurocrine Biosciences USD 779.7M 40.6M 2026-09
Pfizer USD 89B 3.81B 2026-09
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 283M 6M 2026-09
Veracyte USD 133.73M 7.37M 2026-09